Sugi Predict

Sugi Predict / Targets / ACE2

ACE2

Angiotensin-converting enzyme 2 · Q9BYF1 · ACE2 on Sugi Atlas →

77,056 patent compounds predicted against ACE2, 48,154 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL197902 SCHEMBL197902 0.58 9/20
SCHEMBL236628 SCHEMBL236628 0.55 7/20
SCHEMBL244885 SCHEMBL244885 0.67 6/20
SCHEMBL71614 SCHEMBL71614 0.57 5/20
SCHEMBL233444 SCHEMBL233444 0.59 4/20
SCHEMBL233445 SCHEMBL233445 0.59 4/20
SCHEMBL180415 SCHEMBL180415 0.56 4/20
SCHEMBL205548 SCHEMBL205548 0.55 4/20
Alacepril Alacepril (SCHEMBL34559) 0.54 4/20
SCHEMBL135150 SCHEMBL135150 0.52 4/20
SCHEMBL247341 SCHEMBL247341 0.56 3/20
SCHEMBL247343 SCHEMBL247343 0.56 3/20
SCHEMBL135366 SCHEMBL135366 0.56 3/20
SCHEMBL135367 SCHEMBL135367 0.56 3/20
SCHEMBL245581 SCHEMBL245581 0.55 3/20
SCHEMBL245582 SCHEMBL245582 0.55 3/20
SCHEMBL221538 SCHEMBL221538 0.54 3/20
SCHEMBL221539 SCHEMBL221539 0.54 3/20
SCHEMBL221540 SCHEMBL221540 0.54 3/20
Hydroxychloroquine Hydroxychloroquine (SCHEMBL8170) 1.00 2/20

Clinical trials — most relevant to ACE2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Telmisartan for Treatment of COVID-19 Patients PHASE4COMPLETED
Stopping ACE-inhibitors in COVID-19 PHASE4COMPLETED
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial PHASE2/PHASE3UNKNOWN
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 PHASE2/PHASE3UNKNOWN
Use of Angiotensin-(1-7) in COVID-19 PHASE1/PHASE2COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID) PHASE2UNKNOWN
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. PHASE1/PHASE2UNKNOWN
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19 PHASE1UNKNOWN
RAS and Coagulopathy in COVID19 EARLY_PHASE1COMPLETED
Estrogen Therapy in Non-severe COVID-19 Patients nanUNKNOWN
ACEI or ARB and COVID-19 Severity and Mortality in US Veterans nanCOMPLETED
Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19 nanUNKNOWN
COVID-19 Vaccine Response in Treated MS Patients nanCOMPLETED
Hypertension in Patients Hospitalized With COVID-19 nanCOMPLETED
Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19 nanCOMPLETED
ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19 nanCOMPLETED
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19). nanCOMPLETED
Association of Circulating ACE2 Levels With COVID-19 nanCOMPLETED
Renin-Angiotensin System Inhibitors and COVID-19 nanUNKNOWN
Renin-Angiotensin-Aldosterone System Inhibitors, Hypertension, and COVID-19 nanUNKNOWN
The Effect of RAAS Blockers on ACE2 Levels nanCOMPLETED
the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection nanCOMPLETED
Electrolyte State in Patients With COVID-19 nanCOMPLETED
Assessing the Effects of a Cannabidiol Derived From Hemp Supplement in Healthy Adults nanCOMPLETED
Cardiac Injury in COVID-19: a Pathology Study nanUNKNOWN
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR) nanCOMPLETED
Treatment of Angiotensin Peptide (1-7) for COVID-19 nanCOMPLETED
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19 nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ACE2 binder may also engage these)

ProteinNameSimilarity
Q8R0I0 — 1.000 Q8R0I0 →
Q5RFN1 — 1.000 Q5RFN1 →
Q56H28 — 1.000 Q56H28 →
Q5EGZ1 — 1.000 Q5EGZ1 →
Q56NL1 — 1.000 Q56NL1 →
Q58DD0 — 1.000 Q58DD0 →
Q10715 — 0.995 Q10715 →
Q6Q4G4 — 0.995 Q6Q4G4 →
F1RRW5 — 0.994 F1RRW5 →
Q10751 — 0.991 Q10751 →
Q10714 — 0.990 Q10714 →
Q9VLJ6 — 0.989 Q9VLJ6 →
ACE Angiotensin-converting enzyme 0.989 landscape →
P07861 — 0.987 P07861 →
Q18673 — 0.987 Q18673 →
D0G895 — 0.987 D0G895 →
Q9NC65 — 0.986 Q9NC65 →
P12822 — 0.986 P12822 →
P16098 — 0.986 P16098 →
Q50JE5 — 0.986 Q50JE5 →
A0A0B4K692 — 0.985 A0A0B4K692 →
Q61391 — 0.985 Q61391 →
Q18581 — 0.985 Q18581 →
A5HUI5 — 0.985 A5HUI5 →
P08049 — 0.985 P08049 →
O77633 — 0.985 O77633 →
P97449 — 0.984 P97449 →
Q06K61 — 0.984 Q06K61 →
O44857 — 0.984 O44857 →
A5PN38 — 0.984 A5PN38 →